Key Points
- HHS restructuring slashes 10,000 jobs department‑wide, with 1,200 positions eliminated at NIH facilities in Maryland. Politico
- Johns Hopkins to cut over 2,200 roles globally; UMB to lay off 30 filled posts and eliminate 30 vacancies. (The Washington Post)
- BioNTech, Regenxbio, Bora, BioFactura and GSK together are among the many companies shedding nearly 1,200 Maryland‑based jobs over the past year.
By Chris Frew, BioBuzz Networks — July 30, 2025
Let me begin by stating that I’m an optimist – but Maryland’s life science labor market is reeling. And, this is the worst it has ever been – even compared to the Great Recession in 2008-09, the year I first started BioBuzz.
After facing nearly four years of headwinds, muted investment and continuous layoffs, the 1-2 punch that sent shock waves across Maryland and the greater Biohealth Capital Region came with President Trump’s cut to Federal research funding, followed by HHS Secretary Robert F. Kennedy Jr’s reorganization plan to reduce the department’s headcount – from 82,000 to 62,000, 10,000 of which through layoffs. Politico reports that the FDA and CDC shoulder the deepest reductions (3,500 and 2,400 jobs, respectively), while NIH will eliminate 1,200 research roles across Maryland (Politico). Maryland WARN filings confirm 2,755 HHS positions were cut at state facilities on May 31st alone, underscoring the local impact.
Perhaps one of Maryland’s proudest claims —hosting 63 federally operated research laboratories, 40 of them in Montgomery County alone, which also ranks among the nation’s leaders in PhD density — is becoming its Achilles’ heel.
The pain has rippled through academia as well. Johns Hopkins University—88% reliant on federal research grants—announced plans to cut over 2,200 roles globally, including 247 U.S. positions, after an $800 million loss of USAID funding and looming NIH indirect‐cost caps The Washington Post. At the University of Maryland, Baltimore, President Bruce Jarrell will lay off 30 filled roles, eliminate 30 vacant positions, and impose salary reductions on roughly 1,000 faculty and staff to close a $33.8 million budget gap driven by state and federal funding shortfalls (CBS News).
In response to recent federal layoffs some organizations such as Bio-Trac® and Montgomery College under the leadership of Mark Nardone, PMP have been stepping up to help displaced scientists by hosting job fairs aimed at connecting them with top biotech and pharmaceutical employers in the BioHealth Capital Region.
Private biotechs have followed suit. Following Emergent BioSolutions’ 2024 shuttering of two Maryland sites that slashed 300 roles (Fierce Pharma), they sold a third site, the Baltimore fill-finish facility, to Bora Pharmaceuticals. Unfortunately, Bora has now laid off an undisclosed number of their workers as well. In Gaithersburg, BioNTech wound down its cell‑therapy operations, cutting 95 employees this year—more than 60% of its local headcount (The Business Journals). Adding to the tally, REGENXBIO announced a 15% workforce reduction this summer, as did MacroGenics who laid off 30 employees, approximately 10% of its workforce. Rockville’s GSK is eliminating 260 jobs from Maryland as it shuts down its Shady Grove vaccine R&D center to relocate operations the Boston area by March 2026 (Fierce Biotech). In Frederick, BioFactura also laid off a portion of its staff due to the elimination of its government small pox contract, and Leidos laid off at least 50 from their operation at the Frederick National Laboratory for Cancer Research.
Once a bright spot, venture investment in Maryland’s BioHealth Capital Region is now in the shadows. While TEDCO has remained active in their early stage investments, the muted levels of follow-on funding shows that cautious life science investors are still holding back which is further reducing jobs at the hundreds of startups and early stage companies across the region.
With direct cuts exceeding 5,000 positions at federal, academic and private employers—and a broader WARN log reflecting more than 1,200 bioscience‑sector layoffs over the past 12 months—the region is grappling with a talent surplus that far outstrips openings at employers and on major life‑science job boards.
The result: thousands of highly skilled professionals face stiff competition for dwindling opportunities as there are not enough jobs at Maryland’s life science employers to absorb the available talent.
If you are unemployed or looking for work we encourage you to create a profile a BioBuzz profile and be part of our talent ecosystem.
Sign up at: app.biobuzz.io
The fallout extends beyond laboratories and offices. Local lab‑service providers, and ancillary businesses—from real‑estate firms to scientific equipment vendors are shedding jobs and cutting costs as their client’s workforce shrinks and budgets tighten. The impact is so rippling when it comes to life science jobs because, according to a 2024 PhRMA report by TEConomy Partners, for every one direct job in the US biopharmaceutical industry, 4.69 additional jobs are supported in other sectors of the economy. Unfortunately, that means that these job losses have a large negative multiplier effect as well.
Another signal to the challenges we’re facing is the record high availability of lab space. In Montgomery county alone, nearly 25% of the county’s 9.5 million square feet of lab space, including space currently occupied, is now available for lease. “It’s probably the most I’ve ever seen in my [23-year] career,” said Matt Brady, President of Rockville real estate firm Scheer Partners in a recent WBJ article. “It’s a very high amount.”
Amongst the troubled waters, there are a few waypoints that signal hope. AstraZeneca’s recently completed $300M cell therapy manufacturing facility in Rockville that will add hundreds of jobs, and Syngene International’s expansion plans at their newly acquired Baltimore BayView CDMO are much needed job growth opportunities for the State, but it’s simply not enough.
Meanwhile, neighboring states are moving to capitalize on Maryland’s woes. Virginia’s Catalyst grants have funded 62 bioscience projects—promising 6,200 jobs and $2.5 billion in investment over five years, not including the $2B commitment from AstraZeneca to build its largest US manufacturing facility in VA. Further south, North Carolina has seen over $11B in biopharma facility investments in the past 18 months adding thousands of jobs to the region. Originally funded with $39 million from a Golden LEAF grant, the BTEC has built a world-class workforce training and relocation incentives infrastructure showing that big investments in workforce development pay off.
In the absence of enough local employers to absorb the thousands of displaced, highly educated life‑science professionals, Maryland will almost certainly see a significant out‑migration of talent. A recent Comptroller’s report found that, even before these cuts, Maryland was experiencing a net migration loss—with more residents moving to lower‑cost states such as North Carolina, South Carolina, Pennsylvania and Florida than relocating here. Deprived of opportunities, many PhDs, research scientists and seasoned lab managers will follow suit—seeking roles in neighboring hubs like Philadelphia, Virginia, Boston, North Carolina, or even overseas where Biotech is seeing double digit growths for the year. Our labs, classrooms and startup pipelines will continue to empty of the very expertise that made the state competitive.
Turning Crisis into Opportunity
Remember that I’m an optimist, so of course I’m looking for the bright side here. I was taught from an early age that every problem has a solution and I believe that there is a path back from this for the industry to become stronger than ever before in our State and region. After spending 20 years working within the regional life science ecosystem and learning the systems, the people and the companies and the possibilities that exist here, I am confident we can prevail – but it means change.
Industry leaders, university partners and state officials must act swiftly to stabilize Maryland’s ecosystem. Without swift action our greatest assets will move away and be depleted.
First, I believe that the solutions that we build need to be driven and guided by industry, and followed with public support. Why, because the industry is in the best position and has the highest motivation to solve these problems and then will be in the lead position to reap the benefits of doing so. I know that the industry has been beaten up the past few years but that’s all the more reason to be willing to come to the table with new ideas.
Secondly, I believe that true collaboration is essential to digging out of this. That means that we must all adopt a rising tide mentality and extend the olive branches to those you may not have partnered with in the past or even felt were competitive. The real competition are those seeking to recruit our companies, our talent and our innovation out of the region. Only together will we retain it.
If you’d like to stay in the know, or get involved in regional initiatives that aim to create jobs, spur innovation and company creation, grow investment in the region, then sign up below and we’ll deliver updates every few weeks to your inbox.
